Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across EuropePaul Hofman, Umberto Malapelle, Fiorella Calabrese et al.|ESMO Open|2023Cited by 28
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized MiceMaura H. Parker, Byoung Y. Ryu, Greyson Hamilton et al.|Blood|2023Cited by 7
Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an <i>In Vivo</i> Anti-CD19 CAR T Cell TherapyAlissa Brandes, Ryan Larson, A. Koo et al.|Blood|2024Cited by 5
438 In vivo Engineered CAR-T cells for oncology using a surface-engineered lentivirus platform: nonclinical safety and biodistributionAlissa Brandes, Ryan Larson, Soo Min Koo et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1
1230 VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance<i>in vivo</i>CAR T cell generation and antitumor activityChris Nicolai, Wai‐Hang Leung, Jim Qin et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0